For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

A multi-institutional observer study of AI-aided oncologists' performance on treatment response assessment of bladder cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...

Some types and grades of bladder cancer spread quickly. Doctors can treat this disease in several ways. However, treatments are most effective before bladder cancer spreads. The bladder is a hollow ...